July's big TV spenders Humira, Lyrica drop $25M each by Beth Snyder Bulik Tuesday, August 14, 2018 AbbVie’s Humira, along with Pfizer’s Lyrica and Xeljanz, each spent more than $25 million on TV advertising for July.
AbbVie, Roche, Pfizer cited for 'exploitative' patent strategy by Angus Liu Monday, August 6, 2018 AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.
AbbVie, Pfizer are becoming an item atop the ad-spend charts by Beth Snyder Bulik Wednesday, May 2, 2018 AbbVie's Humira and Pfizer's Lyrica once again rank No. 1 and No. 2 on our April list for pharma TV ad spending, according to iSpot.tv data.
No need for a megamerger, Pfizer CEO says. Our pipeline's got it by Eric Sagonowsky Tuesday, May 1, 2018 Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.
No March madness for pharma ad spending as Humira tops list by Beth Snyder Bulik Wednesday, April 11, 2018 AbbVie’s Humira and Pfizer’s Lyrica remained in the top two spots for pharma TV ad spending in March, according to realtime TV ad tracker iSpot.tv.
Pfizer's Ibrance joins February's TV ad-spending leaders by Beth Snyder Bulik Friday, March 23, 2018 Debut ads helped drive list-toppers for pharma TV spend in February, with Ibrance, Otezla, Rexulti, Entresto and Eliquis entering the top 10.
Pfizer could face £502M bill for Lyrica in U.K.: study by Eric Sagonowsky Monday, February 26, 2018 Pfizer could be on the hook for £502 million in National Health Service spending on Lyrica if a patent appeal fails, according to a new study.
AbbVie, Pfizer lead pharma TV ad in 2018 start by Beth Snyder Bulik Wednesday, February 7, 2018 It’s a new year of TV ad spending in pharma, and AbbVie's Humira and Pfizer's Lyrica started with a bang at more than $35 million each last month.
Humira back on top of TV ad spend, ahead of Lyrica and Victoza by Beth Snyder Bulik Monday, November 6, 2017 After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.
